FDA
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $208 at Stifel: Arikayce Peak Sales Revised Upwards
-
-
-
-
-
-
-
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $121 at Jefferies
-
-
-
-
-
-
-
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
-
-
-
-
-
-
-
Insmed (INSM): FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
-
325,451 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

